title: Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents.
abstract: For several decades, cytotoxic chemotherapeutic agents were considered the basis of anticancer treatment for patients with metastatic tumors. A decrease in tumor burden, assessed by volumetric computed tomography and magnetic resonance imaging, according to the response evaluation criteria in solid tumors (RECIST), was considered as a radiological response to cytotoxic chemotherapies. In addition to RECIST-based dimensional measurements, a metabolic response to cytotoxic drugs can be assessed by positron emission tomography (PET) using (18)F-fluoro-thymidine (FLT) as a radioactive tracer for drug-disrupted DNA synthesis. The decreased (18)FLT-PET uptake is often seen concurrently with increased apparent diffusion coefficients by diffusion-weighted imaging due to chemotherapy-induced changes in tumor cellularity. Recently, the discovery of molecular origins of tumorogenesis led to the introduction of novel signal transduction inhibitors (STIs). STIs are targeted cytostatic agents; their effect is based on a specific biological inhibition with no immediate cell death. As such, tumor size is not anymore a sensitive end point for a treatment response to STIs; novel physiological imaging end points are desirable. For receptor tyrosine kinase inhibitors as well as modulators of the downstream signaling pathways, an almost immediate inhibition in glycolytic activity (the Warburg effect) and phospholipid turnover (the Kennedy pathway) has been seen by metabolic imaging in the first 24 h of treatment. The quantitative imaging end points by magnetic resonance spectroscopy and metabolic PET (including 18F-fluoro-deoxy-glucose, FDG, and total choline) provide an early treatment response to targeted STIs, before a reduction in tumor burden can be seen.
authors.affiliation: Department of Anesthesiology, University of Colorado Comprehensive Cancer Center, Aurora, CO, USA; Developmental Therapeutics Program, University of Colorado Comprehensive Cancer Center, Aurora, CO, USA.
authors.forename: Natalie J
authors.initials: NJ
authors.lastname: Serkova
authors.affiliation: Developmental Therapeutics Program, University of Colorado Comprehensive Cancer Center, Aurora, CO, USA; Division of Medical Oncology, Anschutz Medical Center, University of Colorado Denver, Aurora, CO, USA.
authors.forename: S Gail
authors.initials: SG
authors.lastname: Eckhardt
keywords: RECIST; chemotherapeutics; magnetic resonance spectroscopy; positron emission tomography; signal transduction inhibitors